Compare BYFC & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BYFC | SERA |
|---|---|---|
| Founded | 1946 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.7M | 77.2M |
| IPO Year | 2013 | 2021 |
| Metric | BYFC | SERA |
|---|---|---|
| Price | $7.60 | $1.99 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.6K | ★ 93.6K |
| Earning Date | 07-31-2025 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.32 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $155,000.00 | $81,000.00 |
| Revenue This Year | N/A | $875.93 |
| Revenue Next Year | N/A | $248.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 5.19 |
| 52 Week Low | $5.51 | $1.37 |
| 52 Week High | $8.85 | $4.09 |
| Indicator | BYFC | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 42.29 | 42.61 |
| Support Level | $7.19 | $1.80 |
| Resistance Level | $7.85 | $2.00 |
| Average True Range (ATR) | 0.06 | 0.21 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 21.43 | 41.98 |
Broadway Financial Corp is active in the financial services domain. It is a savings and loan holding company in the United States. The Bank's business consists of deposits from the general public and using such deposits, together with borrowings and other funds, to make mortgage loans secured by residential properties and commercial real estate. Its deposits consist of passbook savings accounts, checking accounts, and negotiable order of withdrawal accounts, money market accounts and fixed-term certificates of deposit. The revenue is derived from interest income on loans and investments.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.